Nantahala Capital Management’s Astria Therapeutics ATXS Stock Holding History

Nantahala Capital Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,069,530	Closed	-$14M	–	154
2025 Q4	$14M	Hold	1,069,530	–	–	0.46%	52
2025 Q3	$7.79M	Hold	1,069,530	–	–	0.27%	80
2025 Q2	$5.73M	Buy	1,069,530 +400,000	+60%	+$1.94M	0.22%	84
2025 Q1	$3.58M	Sell	669,530 -5,470	-0.8%	-$38.3K	0.14%	89
2024 Q4	$6.03M	Hold	675,000	–	–	0.26%	69
2024 Q3	$7.43M	Hold	675,000	–	–	0.38%	58
2024 Q2	$6.14M	Buy	+675,000	New	+$6.59M	0.36%	55

Nantahala Capital Management's ATXS Position: Q1 2026 in Review

Nantahala Capital Management sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 1,069,530 shares — an estimated $14M sold.

Nantahala Capital Management first reported a position in ATXS in Q2 2024 and held it in 7 quarters. The position peaked at $14M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Nantahala Capital Management reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Nantahala Capital Management sold 1,069,530 Astria Therapeutics shares in Q1 2026, an estimated $14M.
Nantahala Capital Management first reported a position in Astria Therapeutics in Q2 2024 and held it in 7 quarters.
Nantahala Capital Management's Astria Therapeutics position peaked at $14M in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.